-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>/* Style Definitions */ sp.
Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment
Insilico's preclinical drug candidate is an oral 3CL protease inhibit.
.
In the early days of the outbreak, in order to combat the new coronavirus, Insilicon used the data on the structure and characteristics of the coronavirus accumulated during the SARS outbreak in 2003 to train its end-to-end artificial intelligence drug research and development platfo.
.
The global epidemic caused by the new coronavirus has had a significant impact on human health and economic development, and brought serious challenges to global public health securi.
Insilico is developing a rapidly growing portfolio of therapies at the forefro.